Abstract
Sex differences in morbidity and mortality have been reported in the cystic fibrosis (CF) population worldwide. However, it is unclear why CF women have worse clinical outcomes than men. In this review, we focus on the influence of female sex hormones on CF pulmonary outcomes and summarise data from in vitro and in vivo experiments on how oestrogen and progesterone might modify mucociliary clearance, immunity and infection in the CF airways. The potential for novel sex hormone-related therapeutic interventions is also discussed.
Abstract
A disparity in survival has been noted between men and women with cystic fibrosis where female sex hormones may facilitate lung disease progression. There is strong evidence that implicates oestrogen in numerous aspects of CF airway pathophysiology. https://bit.ly/34ef4Cv
Introduction
Cystic fibrosis (CF) is a multi-system genetic disease due to defects in the CF transmembrane conductance regulator (CFTR) protein, most commonly affecting the lungs. This manifests as chronic airway infection and inflammation, and recurrent pulmonary exacerbations, which account for the majority of morbidity and mortality seen in CF. Other risk factors associated with mortality include certain CFTR genotypes, poor nutritional status, development of CF-related diabetes (CFRD), low socioeconomic status, minority race or ethnicity and female sex [1, 2]. Indeed, researchers have identified a persistent disadvantage in clinical outcomes and survival for female CF patients compared to their male counterparts. This disparity in outcomes between sexes is not limited to CF as a number of other respiratory diseases, such as asthma, also have worse reported outcomes in women [3]. While there are some anatomical differences between males and females, such as smaller airway diameter and lung volumes in women, that might contribute to differences in respiratory disease outcomes [4], many have theorised that sex hormones may be contributing to differences in CFTR expression/function, mucus and airway fluid characteristics, as well as airway infection and inflammation. Here, we provide a focused review of the literature on the influence of oestrogen and progesterone on CF airway pathophysiology and pulmonary outcomes.
The “gender gap” in CF survival and pulmonary outcomes
The gap in clinical outcomes between men and women with CF has been well documented in epidemiological studies [5] and confirmed over time with registry data worldwide. The 2017 CF Canada registry reported a median survival age of 56 years for males and just 49 years for females [6]. Similarly, this discrepancy is seen in registry data from the USA, UK, Scandinavia and Australia where women also experience a higher rate of morbidity and mortality [5, 7–10].
Women demonstrate earlier or more frequent acquisition of organisms associated with worse outcomes including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, methicillin-resistant Staphylococcus aureus (MRSA), Burkholderia species, fungal and non-tuberculous mycobacterial species [8, 9, 11]. Women also need more intense and complex pulmonary exacerbation treatment regimens and require longer lengths of hospitalisation [8, 9]. As well, CFRD is a more common complication in women and they experience a larger drop in lung function and a greater mortality rate after developing CFRD than men [12, 13], though the cause for this remains unclear.
The cause of this “gender gap” is likely multifactorial, related to intrinsic physiological differences as well as biochemical, nutritional and behavioural differences between the sexes. Women, on average, have a smaller airway diameter with smaller lung volume, even adjusted for height, which has been speculated to represent an anatomical impediment to mucus clearance particularly from airways with sharp-angled bifurcations or trifurcations [3]. In addition, women are predisposed to a higher degree of airway hyperresponsiveness and bronchoconstriction [3, 4]. This increased propensity for bronchoconstriction in physiologically smaller airways may result in more frequent and exaggerated narrowing of inflamed airways during periods of exacerbations, leading to more mucus production and impaction, thus perpetuating the vicious cycle of inflammation and recurrent bacterial infections. Furthermore, body mass index (BMI) has been well documented to be lower in CF women compared to CF men and is significantly lower than age-matched non-CF women starting at a younger age [14]. Given the reported desirability of having a lower weight, CF women are likely to be more resistant to nutritional interventions that help to increase their weight [15]. Vertical growth, another indicator of nutritional status, is also stunted in CF girls compared to age-matched non-CF girls, while the same disparity is not seen in CF boys [16]. Poor nutritional status and reduced BMI are associated with lower lung function and increased mortality in CF [9, 14, 16], and therefore undoubtedly contribute to the sex disparity in CF survival. Furthermore, CF women have been found to have poorer medication and nutritional adherence, which may also contribute to reduced lung function [17, 18] and worse health outcomes [19].
Despite accounting for differences in BMI, lung function, CFRD status and chronic bacterial infections between the sexes, female sex remains an independent risk factor for death [9]. It has been noted that sex differences in outcomes seem to only manifest after puberty as rates of pulmonary exacerbations and mortality are similar between boys and girls before puberty but are more common in women than men in adulthood [20, 21]. Therefore, disparity in morbidity and mortality between sexes may also be related to post-pubertal female hormonal changes.
Physiology of female sex hormones
Biology of female sex hormones
The predominant female sex hormones are oestrogen and progesterone. Oestrogen is mainly produced from cholesterol by the ovaries, the corpus luteum and the placenta [22] but can also be produced in extra-gonadal sites including peripheral adipose tissue and the lungs via the enzyme aromatase. Physiological oestrogens exist in three biochemical forms: oestrone, oestradiol (or 17-β-oestradiol) and oestriol. Oestradiol is the most potent and predominant form of oestrogen found in premenopausal women, while oestrone is the most active form of oestrogen in menopausal women and oestriol is the main active form of oestrogen during pregnancy. All three forms of oestrogen are transported in the bloodstream either bound to sex hormone-binding globulin or in the unbound state [23] before binding to either oestrogen receptors (ER) α or β expressed on the cell surface of the target tissue [24]. Notably, both oestrogen receptors are expressed in lung epithelia, airway smooth muscle and the pulmonary vasculature [25, 26]. The activated oestrogen/ER complex has been implicated in fetal alveologenesis and surfactant production, pulmonary arterial hypertension, airway hyperresponsiveness and pulmonary inflammation [25].
Progesterone is likewise produced from cholesterol [27] and readily diffuses across cellular membranes and binds intracellular progesterone receptors A and B. Progesterone receptors are expressed in a number of target tissues, including lung airway epithelium and T-lymphocytes [27–29]. Within the lungs, progesterone has been noted to mediate bronchodilation by reducing contractility and increasing smooth muscle relaxation, confer protection from viral injury and reduce ciliary beat frequency in vitro [28–30].
Menstrual physiology
In order to understand changes in CF clinical outcomes in the context of female sex hormone fluctuations, the physiological pattern of oestrogen and progesterone change should first be described. While the levels of these hormones are endogenously produced at a higher level in women than in men, oestrogen and progesterone levels fluctuate with monthly menstrual cycles in females of childbearing age. At the start of the cycle, or menstruation, both oestrogen and progesterone levels are low (figure 1). Oestrogen levels subsequently rise and peak, while progesterone levels remain low during the follicular phase (the period of time pre-ovulation) and ovulation. In contrast, during the luteal phase (the period of time after ovulation), both progesterone and oestrogen levels rise before falling again in concert with the start of the next menstrual cycle.
Changes in oestrogen and progesterone levels in the context of clinical, infectious and inflammatory findings during the menstrual cycle. During the menstrual phase, both oestrogen and progesterone levels are low. In the follicular phase, oestrogen begins to rise and peak just prior to ovulation. Progesterone begins to rise shortly before ovulation and peak during the luteal phase. Oestrogen levels also increase during the luteal phase. Levels of both progesterone and oestrogen decline until the start of the next menstrual cycle. Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) are both noted to be reduced during menstruation and ovulation but recover to baseline by the luteal phase. Rates of pulmonary exacerbations (PEx) are highest during the follicular phase, while markers of inflammation (tumour necrosis factor-α (TNF-α), interleukin-8 (IL-8) and free neutrophil elastase (NE)) and Pseudomonas aeruginosa (PsA) sputum bacterial load are highest during ovulation. PsA takes on the more virulent mucoid form during the follicular phase while reverting to the less virulent non-mucoid form during the luteal phase.
Effects of female sex hormones on CF pathophysiology
As lung disease is a major determinant of survival in CF, sex differences in airway mechanics may contribute to the “gender gap”. The clinical observation of worsening airway infection and inflammation that correspond to increases in the physiological levels of oestrogen and progesterone in women suggest a plausible mechanistic link between sex hormones and CF airway pathophysiology [31].
Impact of sex hormones on mucociliary clearance
Mucociliary clearance is influenced by a number of factors in the CF patient. The CFTR protein is expressed on the mucosal surface of epithelial cells throughout the body, regulating the secretion and absorption of ions and fluids. Ion transport helps to regulate the pH and viscosity of airway surface liquid (ASL), a thin fluid layer that sits above the epithelium. Adequate ASL volume is essential for effective mucociliary clearance. In addition, mucus production is a physiological response to the presence of airway debris and microorganisms. CF patients produce more viscous mucus, in part due to CFTR dysfunction, which hampers mucociliary clearance. Suboptimal mucociliary clearance results in retained secretions, mediating an increased vulnerability to recurrent airway infection and inflammation. To understand the link between sex hormones and mucociliary clearance, a number of research groups have examined the effect of oestrogen and progesterone on CFTR expression, CFTR-dependent and CFTR-independent ion transport, ASL and mucus production.
In vitro studies have demonstrated that CFTR expression is either unchanged [32] or even increased in response to oestrogen and/or progesterone exposure [32–34]. In a bronchial epithelial cell line expressing F508del mutated CFTR protein, Casavola and colleagues [35] demonstrated that the defect in CFTR localisation and CFTR-mediated chloride secretion could be reversed upon oestrogen stimulation, mediated through the upregulation of the sodium hydrogen exchanger regulatory factor (NHERF1). Similar improvements in CFTR-mediated chloride secretion can be seen in other cell types, such as rabbit pancreatic acinar cells [32]. Conversely, oestrogen appears to have a negative effect on CFTR-independent chloride channel activity. Tarran and colleagues [36] have demonstrated that 17-β-oestradiol can cause increased viscosity of ASL in a dose-dependent fashion by impairing Ca2+-mediated chloride secretion. Similarly, KCNE3 (MinK-related peptide 2) is a protein expressed in tracheal epithelia that regulates KCNQ1 (potassium voltage-gated channel subfamily Q member 1) and has been implicated in the pathophysiology of CF as it indirectly mediates chloride secretion independent of CFTR [37]. Oestrogen has been shown to disrupt the interaction between KCNE3 and KCNQ1, leading indirectly to reduced chloride ion secretion and therefore thicker mucus production [38]. The binding of oestradiol to the oestrogen receptor α in airway epithelial cells has also been shown to increase mucin (MUC5B) production from the submucosal glands, potentially promoting mucus plugging in the CF airways [39]. Finally, oestrogen has also been shown to reduce the intensity of ciliary beat of the CF bronchial epithelium, further hampering the CF airways' ability to clear thickened secretions [40]. Conversely, in non-CF airway epithelium, oestrogen has been shown to increase the intensity of cilia beat frequency and counteracts the negative effects of progesterone on ciliary function [28]. Thus, more work will be needed to understand why oestrogen appears to play opposing roles in CF and non-CF airways.
Collectively, these findings suggest that while oestrogen may directly improve CFTR expression and function, there are also a number of mechanisms whereby oestrogen can indirectly reduce chloride secretion and thicken mucus/ASL to reduce mucociliary clearance overall.
Impact of sex hormones on immunity and infection
Female sex hormones, and oestrogen in particular, have been studied in the context of a number of inflammatory, infectious and autoimmune diseases. Depending on the specific arm of the immune response and the disease model, oestrogen has been implicated in both enhancing and suppressing immunity. In general, women tend to have more robust T-cell immunity, which is particularly beneficial in anti-viral defence [41, 42], but exuberant T-helper (Th)-2 response, eosinophilic inflammation and IL-33 production have been implicated in worsening asthma and autoimmune conditions [43, 44]. Conversely, oestrogen appears to hamper the innate immune response to bacterial infections [45]. Sex hormones have also been shown to have pleotropic effects on CF inflammation and vulnerability to bacterial infections. As CF pulmonary exacerbations are frequently mediated by chronic bacterial infections, a sex disparity in bacterial infection response may therefore increase the risk of infection and inflammation in CF women.
The production of lactoferrin, an antimicrobial peptide that is part of the innate defence against invading pathogens, was found to be significantly reduced when oestrogen-stimulated mice were infected with P. aeruginosa compared to mice without oestrogen stimulation [46]. McElvaney and colleagues [47] demonstrated that 17-β-oestradiol mediates an increase in secretory leukoprotease inhibitor (SLPI) production in CF bronchial epithelial cells, resulting in the downregulation of interleukin (IL)-8 production via the Toll-like receptor (TLR)–nuclear factor-κB signalling pathway. As IL-8 is a chemokine responsible for neutrophil chemotaxis, inhibition of IL-8 production could therefore result in the downregulation of the innate immune response to infections in CF patients. In addition to reduced neutrophilic chemotaxis, oestrogen can also reduce neutrophil-mediated bacterial clearance as neutrophils isolated from oestrogen-treated mice demonstrate increased oxidative burst but reduced P. aeruginosa killing when compared to progesterone-treated controls [48]. Oestrogen also appears to promote the Th17 response during P. aeruginosa infection as CF mice stimulated with oestrogen demonstrated higher levels of IL-23 and IL-17 in lung tissue and bronchoalveolar fluid when compared to mice without oestrogen stimulation, but despite this, the recovered bacterial load from lung homogenate was paradoxically higher [46]. This suggests that while oestrogen may promote neutrophilic oxidative burst and Th17 response resulting in increased host inflammation and presumably more lung tissue injury, neither response is effective in bacterial clearance. Consistent with this, oestrogen-treated ovariectomised female CF mice were found to have worse survival upon inoculation with P. aeruginosa compared to progesterone-treated mice [48].
In addition to modulating the immune response, oestrogen might also directly alter bacterial behaviour. In vitro stimulation with oestradiol was found to enhance the growth of P. aeruginosa, promoting the development of the mucoid phenotype via the upregulation of the bacterial mucA gene [49]. Sputum analyses performed during CF patients' menstrual cycle demonstrated a predominance of the mucoid phenotype in the follicular phase (high oestrogen, low progesterone state), while the non-mucoid phenotype predominated during the luteal phase (low oestrogen, high progesterone state) [49]. Mucoid P. aeruginosa is associated with heightened production of alginate, an integral component of biofilm formation. More recently, oestrogen has also been shown to promote virulence factor expression in P. aeruginosa isolates, leading to increased P. aeruginosa motility as well as increased biofilm formation [40]. Thus, oestrogen may select for a form of P. aeruginosa that is more resistant to host or antimicrobial killing.
Little is known about progesterone's effect on infection and inflammation in CF. During pregnancy in non-CF patients, progesterone has been demonstrated to promote Th2 cytokine production while reducing the Th1 cytokine response, playing a critical role in the prevention of fetal rejection by the maternal immune system [50]. In addition, progesterone has been shown to act upon murine pulmonary epithelium to reduce cellular damage and improve lung function post influenza infection by increasing transforming growth factor-β, IL-6 and IL-22, as well as inducing the proliferation of CD39+ Th17 cells [51]. Progesterone may also be involved in promoting serological responses and T-cell memory, as mice treated with progesterone demonstrate increased antibody titres and lower viral load upon influenza re-infection [52]. Thus, progesterone appears to play an important role in the host immune response to viral infection in murine models, but its role in humans and more specifically CF remains to be seen.
While traditionally considered male sex hormones, androgens are also present in females but at a relatively lower level. “Androgen” is a broad term that encompasses a number of sex hormones including testosterone, dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEA-S) [26]. In non-CF men, testosterone treatment has been shown to be anti-inflammatory, reducing the Th2 response as well as markers of systemic inflammation such as C-reactive protein (CRP) [53]. DHEA-S levels have been demonstrated to inversely correlate with levels of CRP [54]. Several groups have compared androgen levels between CF and non-CF patients. In one small study, serum testosterone levels in five ovulatory CF women were found to be comparable to those in 15 ovulatory non-CF women [55]. More recently, Shaffer et al. [56] reported lower DHEA-S levels in CF women compared to CF men and non-CF women despite comparable levels between non-CF women and men. It is not clear currently what the clinical implications of the reduced DHEA-S level might be, but this may be a contributing factor to the increased inflammation seen in CF women.
Effects of female sex hormones on pulmonary outcomes
As oestrogen has been linked to reduced mucociliary clearance and worsening bacterial infection, one could infer that any period of time when oestrogen exposure is heightened there might be increased pulmonary complications and, on the contrary, attenuating the oestrogen surge might mitigate this effect. However, studies examining the relationship between endogenous or exogenous sex hormones and pulmonary outcomes in CF have been conflicting, and therefore the relationship is likely to be much more complicated (table 1).
Summary of animal and human studies in cystic fibrosis (CF) examining the effects of female sex hormones or cystic fibrosis transmembrane conductance regulator (CFTR) modulators
Endogenous changes
At clinical baseline, women with CF have comparable levels of serum oestradiol to non-CF women [57]. Interestingly, Chotirmall and colleagues [49] found that during periods of CF exacerbations, serum oestradiol levels are significantly higher. They also demonstrated a correlation between serum levels of oestradiol and the frequency of infectious pulmonary exacerbations where the majority of events occurred during the follicular phase (high oestrogen, low progesterone) [49]. Furthermore, registry data collected during pregnancy, a period of time where oestrogen and progesterone are both heightened (table 2), suggest that annual rates of pulmonary exacerbations [58] and haemoptysis [59] are higher compared to non-pregnant female controls. However, it should be noted that the increased rates of exacerbations found during pregnancy might simply be a reflection of increased frequency and intensity of monitoring or other non-hormone related physiological changes in pregnancy (such as increased acid reflux) that heighten the risk of pulmonary complications. Nevertheless, these observations support the hypothesis that elevations in oestrogen may have a detrimental effect on pulmonary infections and presumably lung function. However, when Johannesson and colleagues [60] monitored 12 CF women during their menstrual cycles, they found a 3–5% reduction in both forced expiratory volume in 1 s (FEV1) and forced vital capacity during menstruation (low oestrogen and progesterone) and ovulation (high oestrogen, low progesterone), which recovered during the luteal phase despite representing a period of high oestrogen and progesterone. Thus, the physiological changes in female sex hormones may have a more complex relationship with fluctuations in lung function and mucociliary clearance.
Serum concentrations of oestradiol and progesterone during the menstrual cycle, pregnancy and with oral contraceptive pill (OCP) use
Exogenous changes
The most commonly used hormone-based combination oral contraceptive pills (OCPs) works by inhibiting ovulation by providing 21 days of low-dose oestradiol and progesterone each month to abrogate the natural rise and fall of oestrogen and progesterone during the menstrual cycle (figure 1). Based on a large retrospective study involving 700 women with CF followed over 5 years, no statistically significant difference with regards to the annual rates of change in FEV1 or in the numbers of pulmonary exacerbations requiring intravenous antibiotics were observed between women using OCPs compared to those who did not [61]. Paired analysis of the same women pre- and post-OCP over 3 years also failed to show any difference in clinical outcomes. A separate retrospective analysis involving the Irish CF registry also did not find a statistically significant difference in outcomes in women using OCPs [49]. However, a trend towards reduction in the number of pulmonary exacerbations requiring treatment with either oral or intravenous antibiotics was seen with longer term OCP use [49]. While such retrospective registry studies can be helpful in identifying possible trends, it should be pointed out that there are a number of OCP products on the market that have different combined concentrations of oestrogen and progesterone or are oestrogen/progesterone monotherapies. As well, OCPs are categorised into monophasic (same dose for 21 days of the month) and multiphasic (escalation in dose throughout the month) products. Consequently, without capturing the details of the type of OCP used, potential effects of oestrogen and progesterone on pulmonary outcomes can be challenging to study in observational studies.
A recent small prospective study presented in abstract form by Jain and colleagues [31] demonstrated that FEV1 increased by 2.5% in women who were started on the OCP when compared to their pre-OCP ovulation phase FEV1. Clinically, assessment of patient reported symptom score using the CF questionnaire – revised (CFQ-R) as well as other patient reported quality of life scores demonstrated clinically significant improvements once the OCP was initiated [62]. Furthermore, prior to OCP initiation, these scores were found to be lower in women during menstruation and ovulation when compared to men. Biochemically, sputum inflammatory markers (including tumour necrosis factor-α, IL-8 and free neutrophil elastase) and P. aeruginosa bacterial load were higher during ovulation than in the menstrual or luteal phases [31]. Importantly, a significant reduction in these sputum bacterial and biomarker findings were seen once the OCP was initiated. Given that the OCP typically provides a consistently lower serum concentration of oestrogen and higher concentration of progesterone than the physiological rise and fall of either sex hormones (figure 1), these clinical observations may suggest that reduction in inflammatory activity and bacterial load may result from either a higher level of progesterone, a combination of lower steady state of oestrogen and higher steady state of progesterone, or the abrogation of physiological hormonal fluctuations.
There has been a rise in the number of individuals identifying as transgender in the USA over the past decade. Hormone therapies are commonly employed at the initial stage of gender transitioning from male to female to target a serum oestradiol level in the range of 100–200 ng·mL−1, similar to that seen during ovulation (table 2). While there is currently no published data on how hormone therapies might influence CF relevant pulmonary outcomes, there is an increased lifetime risk of developing asthma in transgender females (male-to-female) relative to transgender males (female-to-male) or non-transgender individuals [63]. In our centre, we currently have a patient who is receiving hormone therapy as part of sex reassignment. Anecdotally, she experienced persistent drops in FEV1 with increased frequency of pulmonary exacerbations, coinciding with oestrogen dose escalation [64]. Similarly, for women experiencing uncomfortable symptoms of menopause, oestrogen and/or progesterone is often prescribed as hormone replacement therapy (HRT) for symptomatic relief. While there is no literature to date on the effects of HRT in the CF population, a prospective analysis involving non-CF individuals examining lung disease outcomes found an increased rate of adult onset asthma with oestrogen only or combination oestrogen/progesterone HRT use [65].
Therapeutic targeting of female sex hormones
In vitro and in vivo studies have demonstrated that oestrogen receptor antagonism may be effective at reversing the oestrogen-mediated pro-inflammatory effects seen in CF airways. Tamoxifen, a selective oestrogen receptor modulator that has both anti-oestrogenic and pro-oestrogenic effects depending on the target tissue, and other non-clinically available oestrogen antagonists have been shown to counteract oestrogen-mediated increases in P. aeruginosa virulence [40]. Tamoxifen has also been shown to improve chloride transport in CF epithelial cells in a CFTR-independent manner by increasing calcium-activated chloride channel currents [66]. While modulating oestrogen levels or oestrogen receptor antagonism has the potential to reduce inflammation and improve pulmonary outcomes in CF females, oestrogen has a wide range of physiological effects including the regulation of menstrual cycles and fertility, bone health and the development of secondary sex characteristics. Therefore, a more targeted approach to altering the downstream effect of oestrogen-mediated inflammation is likely to be a more prudent strategy. In addition, it has been observed that the disparity between men and women with regards to pulmonary exacerbation rates can be improved or even abolished in women treated with CFTR modulators such as ivacaftor [67] or lumacaftor-ivacaftor [68], suggesting that improvements in CFTR expression, localisation or function might be sufficient to counteract the negative effects of oestrogen on CFTR-independent pathways, infection, inflammation and mucociliary clearance.
Unlike oestrogen, much less attention has been paid towards the potential therapeutic benefits of progesterone treatment. Studies of female physiology during pregnancy demonstrate that progesterone has a bronchodilatory effect on the airways through relaxation of smooth muscle tone [69]. Thus, therapeutic dosing of progesterone to mimic levels achieved in pregnancy (table 2) might be a viable intervention. As the progesterone-only OCP is much less popular than the combined OCP due to the concern about accelerated bone loss with both short- and long-term use [70, 71], there is little observational data on the effect of progesterone alone. Given that the therapeutic concentration of progesterone provided in the combined OCP is higher than the physiological level of progesterone during ovulation (table 2), the reduction in sputum inflammation seen with OCP use [31] might be attributable to higher progesterone levels alone. Alternatively, given that the OCP provides a steady-state concentration of progesterone, eliminating the typical rise and fall of sex hormones throughout the menstrual cycle, the improvement in sputum inflammation could also be due to the abrogation of large swings in sex hormone levels. Consequently, further understanding of the effect of progesterone on human lung inflammation will be important before considering the therapeutic use of progesterone in this context.
Future research
The study of sex hormones and CF holds much potential not only for furthering our understanding of inflammation and infection in CF host–pathogen interactions but also for the design of novel therapeutics to help reduce pulmonary-related morbidity and mortality. Several key areas warrant further investigation to achieve these goals. First, further research is needed to understand the mechanistic role that progesterone and the complex interaction between oestrogen and progesterone stimulation might have on mucociliary clearance and bacterial response. While in vitro work demonstrates that oestrogen alone is pro-inflammatory and promotes bacterial survival, clinical observations of improved pulmonary outcomes during the luteal phase (high oestrogen and progesterone) when compared to the follicular phase or ovulation (both high oestrogen and low progesterone states) suggest that the mere presence of high levels of oestrogen does not always result in worse pulmonary outcomes. Given that oestrogen and progesterone levels are similar in men and menstruating women, the fluctuations or surges in sex hormone levels during the female menstrual cycle might be more important than the absolute level of the hormones themselves. Thus, the effect of progesterone and the cyclical changes in oestrogen and progesterone exposure to CF airways merits further investigation. Second, as sex hormones have a myriad of endocrinological effects, oestrogen and progesterone-based therapy may not be a viable intervention to reduce pulmonary exacerbations. Therefore, further research should be focused on finding downstream components of the pro-inflammatory pathway mediated by oestrogen receptor activation that might be a more specific target for therapeutic intervention, such as the SLPI. Further mechanistic studies should be directed to better understand the oestrogen receptor pathway in bronchial epithelial cells to look for other specific localised targets without causing other unintended endocrinological effects.
Conclusion
While it currently remains unclear why a sex disparity exists in CF survival, studies performed over the last several decades have provided evidence that sex hormones might contribute to poor pulmonary outcomes in females by impairing mucociliary clearance and the immune response to infection, increasing bacterial virulence and increasing lung inflammation. Additional research is needed to clarify the role of progesterone on CF airways and to identify specific treatments that counteract the negative effects of female sex hormones on CF airway pathophysiology to improve outcomes in women with CF without causing broader endocrinological complications.
Footnotes
Author contributions: G.Y. Lam: conceptualisation, funding acquisition and writing – original draft. J. Goodwin and P.G. Wilcox: writing – review and editing. B.S. Quon: supervision, funding acquisition and writing – review and editing. All authors read and approved the manuscript.
Conflict of interest: G.Y. Lam has nothing to disclose.
Conflict of interest: J. Goodwin has nothing to disclose.
Conflict of interest: P.G. Wilcox has nothing to disclose.
Conflict of interest: B.S. Quon reports speaker fees from Vertex Pharmaceuticals, advisory board fees from Proteostasis Therapeutics, and grants from CF Canada, the CF Foundation, Gilead Sciences and the BC Lung Association, outside the submitted work.
Support statement: A CF Canada Gilead Sciences Fellowship Award (G.Y. Lam) and a Michael Smith Foundation for Health Research Scholar award (B.S. Quon) provided funding for clinician research time to prepare this manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received July 7, 2020.
- Accepted October 13, 2020.
- Copyright ©ERS 2021
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
References
